Josefine Gradman
Research Subjects
Research Interests
Josefine Gradman has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Ole D. Wolthers
Children’s Clinic Randers, Randers, Denmark
4 shared publicationsMark F. Caldwell
1 shared publicationOle D Wolthers
Children's Clinic Randers, Randers, Denmark
1 shared publication
Latest Publications
- 18 February 2010
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 21 (1-Part-II) , e206-e212
A randomized trial of lower leg and height growth in children with asthma treated with inhaled budesonide from a new dry powder inhaler
Gradman J, Wolthers OD. A randomized trial of lower leg and height growth in children with asthma treated with inhaled budesonide from a new dry powder inhaler. Pediatr Allergy Immunol 2010: 21: e206–e212. © 2009 The Authors Journal compilation © 2009 Blackwell MunksgaardShort‐term knemometry is a highly sensitive and accurate method for non‐invasive assessment of systemic activity of inhaled corticosteroids in children with asthma. However, there are no randomized data available to elucidate the relation between inhaled corticosteroid suppressed short‐term lower leg and height growth. The aim of the present study was to assess the relation between short‐term lower leg and 1‐yr height growth in children with asthma treated with inhaled budesonide from the new Pulairmax® inhaler 200 μg once daily in the morning or montelukast 5 mg once daily. A total of 52 pre‐pubertal children with asthma were included in a randomized open‐label parallel group study. Length of the lower leg and height were measured by knemometry and stadiometry, respectively, at study entry and after 2, 4, 12, 20, 28, 36, 44 and 52 wks. Lower leg and height growth rates were significantly lower in the budesonide than in the montelukast group (p < 0.0001). Mean 2‐wks lower leg growth rate was 0.17 mm/wk in the budesonide and 0.39 mm/wk in the montelukast treated children (p = 0.02). Mean 1‐yr height growth rate was 5.51 cm/yr in the budesonide and 6.51 cm/yr in the montelukast group [95% CI: (0.20; 1.79)]. There was a strong linear correlation between lower leg and height growth in both groups, rho = 0.96 (budesonide) and 0.98 (montelukast). In conclusion, 1‐yr height growth suppression of budesonide 200 μg administered via the Pulairmax® inhaler once daily in the morning was indicated from suppressed short‐term lower leg growth providing evidence that short‐term knemometry is able to predict 1‐yr height growth suppression of inhaled corticosteroids. Short‐term knemometry should be performed as part of the safety assessments of new inhaled corticosteroids and inhalation devices in children with asthma before long‐term height growth evaluations are initiated.
- 18 February 2010
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 21 (1-Part-II) , e206-e212
A randomized trial of lower leg and height growth in children with asthma treated with inhaled budesonide from a new dry powder inhaler
Gradman J, Wolthers OD. A randomized trial of lower leg and height growth in children with asthma treated with inhaled budesonide from a new dry powder inhaler. Pediatr Allergy Immunol 2010: 21: e206–e212. © 2009 The Authors Journal compilation © 2009 Blackwell MunksgaardShort‐term knemometry is a highly sensitive and accurate method for non‐invasive assessment of systemic activity of inhaled corticosteroids in children with asthma. However, there are no randomized data available to elucidate the relation between inhaled corticosteroid suppressed short‐term lower leg and height growth. The aim of the present study was to assess the relation between short‐term lower leg and 1‐yr height growth in children with asthma treated with inhaled budesonide from the new Pulairmax® inhaler 200 μg once daily in the morning or montelukast 5 mg once daily. A total of 52 pre‐pubertal children with asthma were included in a randomized open‐label parallel group study. Length of the lower leg and height were measured by knemometry and stadiometry, respectively, at study entry and after 2, 4, 12, 20, 28, 36, 44 and 52 wks. Lower leg and height growth rates were significantly lower in the budesonide than in the montelukast group (p < 0.0001). Mean 2‐wks lower leg growth rate was 0.17 mm/wk in the budesonide and 0.39 mm/wk in the montelukast treated children (p = 0.02). Mean 1‐yr height growth rate was 5.51 cm/yr in the budesonide and 6.51 cm/yr in the montelukast group [95% CI: (0.20; 1.79)]. There was a strong linear correlation between lower leg and height growth in both groups, rho = 0.96 (budesonide) and 0.98 (montelukast). In conclusion, 1‐yr height growth suppression of budesonide 200 μg administered via the Pulairmax® inhaler once daily in the morning was indicated from suppressed short‐term lower leg growth providing evidence that short‐term knemometry is able to predict 1‐yr height growth suppression of inhaled corticosteroids. Short‐term knemometry should be performed as part of the safety assessments of new inhaled corticosteroids and inhalation devices in children with asthma before long‐term height growth evaluations are initiated.
- 1 March 2008
- Published by Wiley in Pediatric Dermatology
- Vol. 25 (2) , 269-270
Suppressive Effects of Topical Mometasone Furoate and Tacrolimus on Skin Prick Testing in Children
Skin prick tests were performed in 12 children with atopic eczema before and after 2 weeks of treatment with topical mometasone furoate and tacrolimus. Both treatments significantly suppressed the allergen wheal size. Mometasone furoate reduced the histamine wheal size as well. Skin prick testing in children treated with topical glucocorticoids or tacrolimus is associated with a risk of false-negative test results.
- 1 March 2008
- Published by Wiley in Pediatric Dermatology
- Vol. 25 (2) , 269-270
Suppressive Effects of Topical Mometasone Furoate and Tacrolimus on Skin Prick Testing in Children
Skin prick tests were performed in 12 children with atopic eczema before and after 2 weeks of treatment with topical mometasone furoate and tacrolimus. Both treatments significantly suppressed the allergen wheal size. Mometasone furoate reduced the histamine wheal size as well. Skin prick testing in children treated with topical glucocorticoids or tacrolimus is associated with a risk of false-negative test results.
- 1 August 2007
- Published by Elsevier in Clinical Therapeutics
- Vol. 29 (8) , 1738-1747
A 2-Week, Crossover Study to Investigate the Effect of Fluticasone Furoate Nasal Spray on Short-Term Growth in Children with Allergic Rhinitis
- 1 August 2007
- Published by Elsevier in Clinical Therapeutics
- Vol. 29 (8) , 1738-1747
A 2-Week, Crossover Study to Investigate the Effect of Fluticasone Furoate Nasal Spray on Short-Term Growth in Children with Allergic Rhinitis
- 23 July 2007
- Published by Wiley in Acta Paediatrica
- Vol. 96 (8) , 1233-1237
Short‐term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus
Background: Treatment with topical glucocorticoids in children with atopic eczema may be associated with systemic adverse effects, such as suppression of growth.Aim: To asses if treatment with topical mometasone furoate 0.1% or topical tacrolimus 0.1% affects short‐term growth in children with atopic eczema. Primary outcome measures were lower leg growth rates measured by knemometry.Methods: Twenty 5‐ to 12‐year‐old prepubertal children with atopic eczema were included in a randomised, investigator‐blind crossover study with five periods: two treatment periods, a run in, a wash out and a run out. All periods were of 2‐week duration. The subjects applied mometasone furoate ointment 0.1% once daily during one treatment period and tacrolimus ointment 0.1% twice daily during the other treatment period.Results: As compared to run in mean lower leg growth rate during mometasone furoate and tacrolimus treatment was reduced by 0.09 and 0.06 mm/week, respectively, (F = 1.12, p = 0.35). Consistently, no statistically significant effects on urine levels of eosinophil protein X and crossed‐linked N‐telopeptides were detected.Conclusion: Treatment with mometasone furoate or tacrolimus does not affect short‐term growth in children with mild to moderate atopic eczema.
- 23 July 2007
- Published by Wiley in Acta Paediatrica
- Vol. 96 (8) , 1233-1237
Short‐term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus
Background: Treatment with topical glucocorticoids in children with atopic eczema may be associated with systemic adverse effects, such as suppression of growth.Aim: To asses if treatment with topical mometasone furoate 0.1% or topical tacrolimus 0.1% affects short‐term growth in children with atopic eczema. Primary outcome measures were lower leg growth rates measured by knemometry.Methods: Twenty 5‐ to 12‐year‐old prepubertal children with atopic eczema were included in a randomised, investigator‐blind crossover study with five periods: two treatment periods, a run in, a wash out and a run out. All periods were of 2‐week duration. The subjects applied mometasone furoate ointment 0.1% once daily during one treatment period and tacrolimus ointment 0.1% twice daily during the other treatment period.Results: As compared to run in mean lower leg growth rate during mometasone furoate and tacrolimus treatment was reduced by 0.09 and 0.06 mm/week, respectively, (F = 1.12, p = 0.35). Consistently, no statistically significant effects on urine levels of eosinophil protein X and crossed‐linked N‐telopeptides were detected.Conclusion: Treatment with mometasone furoate or tacrolimus does not affect short‐term growth in children with mild to moderate atopic eczema.
- 2 October 2006
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 17 (7) , 524-526
Allergic conjunctivitis in children with asthma, rhinitis and eczema in a secondary outpatient clinic
Little evidence is available on the prevalence of allergic conjunctivitis in pediatric populations. The objective of this study was to assess the cumulative prevalence of allergic conjunctivitis in children with rhinitis, asthma and eczema in a secondary pediatric outpatient clinic. Children aged 5–15 yr referred during the period of 2002–2004 in whom allergic conjunctivitis, asthma, allergic rhinitis or eczema was diagnosed were included in a retrospective survey. At referral patient characteristics, history, symptoms, signs and results of type 1 allergy tests were entered into an electronic form. Four hundred and fifty‐eight children with a mean age of 9.4 yr were studied. Of 316, 324 and 149 children with rhinitis, asthma or eczema, respectively, 133 (42%), 78 (24%) and 45 (30%) had concomitant allergic conjunctivitis. One hundred and thirty‐seven (30%) had allergic conjunctivitis, of whom 133 (97%) also had allergic rhinitis, 77 (56%) asthma and 45 (33%) eczema. One hundred and twenty‐five (91%) of the children with allergic conjunctivitis had positive allergy tests to one or more allergens, sensitization to house dust mites being more frequent in chronic allergic conjunctivitis than in acute allergic conjunctivitis (95% vs. 53%; p < 0.01). Sensitization to grass was more frequent in children with acute allergic conjunctivitis (78% vs. 57%; p = 0.03). In a secondary pediatric outpatient clinic allergic conjunctivitis is a frequent co‐morbidity to allergic rhinitis and to asthma and eczema. Allergic conjunctivitis need to be included as an important co‐morbidity in future guidelines on asthma, rhinitis and eczema management.
- 2 October 2006
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 17 (7) , 524-526
Allergic conjunctivitis in children with asthma, rhinitis and eczema in a secondary outpatient clinic
Little evidence is available on the prevalence of allergic conjunctivitis in pediatric populations. The objective of this study was to assess the cumulative prevalence of allergic conjunctivitis in children with rhinitis, asthma and eczema in a secondary pediatric outpatient clinic. Children aged 5–15 yr referred during the period of 2002–2004 in whom allergic conjunctivitis, asthma, allergic rhinitis or eczema was diagnosed were included in a retrospective survey. At referral patient characteristics, history, symptoms, signs and results of type 1 allergy tests were entered into an electronic form. Four hundred and fifty‐eight children with a mean age of 9.4 yr were studied. Of 316, 324 and 149 children with rhinitis, asthma or eczema, respectively, 133 (42%), 78 (24%) and 45 (30%) had concomitant allergic conjunctivitis. One hundred and thirty‐seven (30%) had allergic conjunctivitis, of whom 133 (97%) also had allergic rhinitis, 77 (56%) asthma and 45 (33%) eczema. One hundred and twenty‐five (91%) of the children with allergic conjunctivitis had positive allergy tests to one or more allergens, sensitization to house dust mites being more frequent in chronic allergic conjunctivitis than in acute allergic conjunctivitis (95% vs. 53%; p < 0.01). Sensitization to grass was more frequent in children with acute allergic conjunctivitis (78% vs. 57%; p = 0.03). In a secondary pediatric outpatient clinic allergic conjunctivitis is a frequent co‐morbidity to allergic rhinitis and to asthma and eczema. Allergic conjunctivitis need to be included as an important co‐morbidity in future guidelines on asthma, rhinitis and eczema management.